These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 49801)

  • 21. Thymectomy for myasthenia gravis: analysis of controversies--patient management.
    Jaretzki A
    Neurologist; 2003 Mar; 9(2):77-92. PubMed ID: 12808370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experimental myasthenia gravis.
    Goldstein G; Hofmann WW
    Res Publ Assoc Res Nerv Ment Dis; 1971; 49():241-59. PubMed ID: 4329690
    [No Abstract]   [Full Text] [Related]  

  • 23. A morphological explanation of the transmission defect in myasthenia gravis.
    Simpson JA
    Ann N Y Acad Sci; 1971 Sep; 183():241-7. PubMed ID: 4330761
    [No Abstract]   [Full Text] [Related]  

  • 24. Blockade of acetylcholine receptors: a model of myasthenia gravis.
    Satyamurti S; Drachman DB; Slone F
    Science; 1975 Mar; 187(4180):955-7. PubMed ID: 1145181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuromuscular transmission in myasthenia gravis studied with single fibre electromyography.
    Stålberg E; Ekstedt J; Broman A
    J Neurol Neurosurg Psychiatry; 1974 May; 37(5):540-7. PubMed ID: 4366058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reflections on the "intrathymic pathogenesis" of myasthenia gravis.
    Hohlfeld R; Wekerle H
    J Neuroimmunol; 2008 Sep; 201-202():21-7. PubMed ID: 18644632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thymopoietin: a marker of the human nicotinic acetylcholine receptor.
    Morel E; Vernet-der-Garabedian B; Raimond F; Audhya TK; Goldstein G; Bach JF
    Ann N Y Acad Sci; 1988; 540():298-300. PubMed ID: 3207258
    [No Abstract]   [Full Text] [Related]  

  • 28. Myf5 and Myogenin in the development of thymic myoid cells - Implications for a murine in vivo model of myasthenia gravis.
    Hu B; Simon-Keller K; Küffer S; Ströbel P; Braun T; Marx A; Porubsky S
    Exp Neurol; 2016 Mar; 277():76-85. PubMed ID: 26708556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thymin: a thymic polypeptide causing the neuromuscular block of myasthenia gravis.
    Goldstein G; Manganaro A
    Ann N Y Acad Sci; 1971 Sep; 183():230-40. PubMed ID: 5287825
    [No Abstract]   [Full Text] [Related]  

  • 30. Some aspects of myasthenia gravis.
    Grashchenkov N; Perelman LB
    Ann N Y Acad Sci; 1966 Jan; 135(1):398-408. PubMed ID: 4287549
    [No Abstract]   [Full Text] [Related]  

  • 31. Myasthenia gravis--the first 100 years in perspective.
    Harvey AM
    Trans Am Clin Climatol Assoc; 1971; 82():149-69. PubMed ID: 4934016
    [No Abstract]   [Full Text] [Related]  

  • 32. The thymus and myasthenia gravis: immunological and neurophysiological aspects.
    Carrieri PB; Marano E; Perretti A; Caruso G
    Ann Med; 1999 Oct; 31 Suppl 2():52-6. PubMed ID: 10574156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of diazepam on muscle weakness in a model of myasthenia gravis in rats.
    Molenaar PC; Van Kempen GT
    J Neural Transm Gen Sect; 1993; 93(3):181-5. PubMed ID: 8217057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent evidence on the neuromuscular block in myasthenia gravis.
    Desmedt JE; Borenstein S
    Electroencephalogr Clin Neurophysiol; 1971 Apr; 30(4):366. PubMed ID: 4103546
    [No Abstract]   [Full Text] [Related]  

  • 35. [Evaluation of remission in childhood myasthenia gravis].
    Ryniewicz B; Emeryk-Szajewska B; Rowińska-Marcińska K; Nowak-Michalska T
    Neurol Neurochir Pol; 1988; 22(2):125-30. PubMed ID: 3405387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contrasting biological activities of thymopoietin and splenin, two closely related polypeptide products of thymus and spleen.
    Audhya T; Scheid MP; Goldstein G
    Proc Natl Acad Sci U S A; 1984 May; 81(9):2847-9. PubMed ID: 6585832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pseudoparalytic myasthenia gravis. Diagnostic and therapeutic aspects in 60 separate cases].
    Mumenthaler M; Lütschg J
    Schweiz Arch Neurol Neurochir Psychiatr; 1976; 118(1):23-56. PubMed ID: 981976
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Experimental myasthenia gravis.
    Kalden JR; Irvine WJ
    Lancet; 1969 Sep; 2(7621):638-9. PubMed ID: 4185607
    [No Abstract]   [Full Text] [Related]  

  • 39. A synthetic pentapeptide with biological activity characteristic of the thymic hormone thymopoietin.
    Goldstein G; Scheid MP; Boyse EA; Schlesinger DH; Van Wauwe J
    Science; 1979 Jun; 204(4399):1309-10. PubMed ID: 451537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
    Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ
    Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.